Please login to the form below

Not currently logged in
Email:
Password:

Former Sanofi exec Joseph Devaney joins Astellas

He becomes government affairs and policy, Americas VP

Astellas Joseph DevaneyAstellas has appointed Joseph Devaney as vice president of government affairs and policy for its Americas business.

In this role, Devaney will be responsible for developing, communicating and implementing Astellas' federal and state government strategies in the US, as well as overseeing its engagement activities and policy development.

He joins the Japanese pharmaceutical firm from Sanofi, where he spent the last 20 years in a series of senior positions, including his most recent post as vice president of federal and state relations.

Prior to this, Devaney was director of state government affairs for Sandoz, which joined Novartis in 1996, and served as a research director and chief of staff for the New Jersey General Assembly.

Jeffrey Winton, senior vice president of corporate affairs at Astellas, said: “Joe's experience and leadership will elevate our highly collaborative team of senior government strategy, policy, legislative and regulatory professionals in Washington, DC.

“His role in developing Astellas' strategy on public policy issues being considered by government lawmakers and trade associations will be pivotal in Astellas' growth throughout the Americas.”

13th July 2016

From: Regulatory

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics